Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
41.17
+0.37 (0.91%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Nektar Therapeutics Market Cap
Nektar Therapeutics has a market cap or net worth of $1.41 billion as of October 9, 2026. It is the 8,478th most valuable company in the world and the 2,025th biggest in the United States. Its market cap has increased by 30.67% in one year.
Market Cap
1.41B
Enterprise Value
857.26M
1-Year Change
30.67%
Global Rank
Country Rank
#2,025 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Nektar Therapeutics's market cap has increased from $478.60M to $1.41B, an increase of 193.70%. That is a compound annual growth rate of 3.94%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 1.41B | 63.45% |
| Dec 31, 2025 | 860.00M | 401.46% |
| Dec 31, 2024 | 171.50M | 59.09% |
| Dec 29, 2023 | 107.80M | -74.62% |
| Dec 30, 2022 | 424.80M | -82.96% |
| Dec 31, 2021 | 2.49B | -18.24% |
| Dec 31, 2020 | 3.05B | -19.69% |
| Dec 31, 2019 | 3.80B | -33.26% |
| Dec 31, 2018 | 5.69B | -39.50% |
| Dec 29, 2017 | 9.40B | 401.47% |
| Dec 30, 2016 | 1.88B | -16.61% |
| Dec 31, 2015 | 2.25B | 12.95% |
| Dec 31, 2014 | 1.99B | 51.06% |
| Dec 31, 2013 | 1.32B | 54.43% |
| Dec 31, 2012 | 853.40M | 33.30% |
| Dec 30, 2011 | 640.20M | -47.19% |
| Dec 31, 2010 | 1.21B | 39.56% |
| Dec 31, 2009 | 868.60M | 68.99% |
| Dec 31, 2008 | 514.00M | -16.91% |
| Dec 31, 2007 | 618.60M | -54.96% |
| Dec 29, 2006 | 1.37B | -4.78% |
| Dec 30, 2005 | 1.44B | -15.13% |
| Dec 31, 2004 | 1.70B | 122.51% |
| Dec 31, 2003 | 763.80M | 70.57% |
| Dec 31, 2002 | 447.80M | -56.04% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Taysha Gene Therapies | 1.44B |
| Hemab Therapeutics Holdings | 1.44B |
| Maze Therapeutics | 1.44B |
| Rapport Therapeutics | 1.43B |
| GH Research | 1.40B |
| Omeros | 1.38B |
| AnaptysBio | 1.38B |
| Tyra Biosciences | 1.37B |